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haemoperfusion (PMX-HP) is a promising adjuvant
strategy for the treatment of sepsis and septic shock.
PMX-HP therapy works by clearing circulating
endotoxin through binding to polymyxin-immobilised
fibres during haemoperfusion. Small clinical trials have
shown that PMX-HP therapy is associated with
improved haemodynamic profile, oxygenation and
survival. However, clear inferences have been largely
inconclusive due to limitations in study design (eg,
small, unblinded) and generalisability. We therefore
propose to perform an up-to-date systematic review
and evidence synthesis to describe the efficacy, safety
and effectiveness of PMX-HP for adult patients with
sepsis or septic shock.
Methods and analysis: We will search the following
databases from 1946 to 2016 MEDLINE (Ovid),
EMBASE (Ovid), Cochrane Library, Health Technology
Assessment Database (HTA), Cumulative Index to
Nursing and Allied Health Literature (CINAHL), PubMed
and ‘Igaku Chuo Zasshi’ (ICHUSHI) for randomised
controlled trials of PMX-HP in critically ill patients with
sepsis or septic shock. There will be no language
restrictions in the electronic search for studies. Two
reviewers will extract data and appraise the quality of
each study independently. The primary outcome will be
the pooled risk ratio of 28-day all-cause mortality.
Serious adverse events and changes in organ
dysfunction scores will also be evaluated. The
secondary outcomes will be 90-day all-cause mortality,
changes in haemodynamic profile and endotoxin levels,
and health services use.
Ethics and dissemination: Our systematic review
will synthesise the evidence on use of the PMX-HP
as an adjuvant therapy in sepsis/septic shock to
improve patient-centred, physiological and health
services outcomes. Research ethics is not required
for this review. The study will be disseminated by
peer-reviewed publication and conference
presentation.
Trial registration number: CRD42016038356.
INTRODUCTION
Description of the condition
Sepsis remains desperately fatal and is a
major cause of mortality in the intensive care
unit (ICU) settings worldwide.1 2 Many
efforts have been made to improve prognosis
in this condition but large multicentred trials
of various innovative therapies have failed to
demonstrate consistent beneﬁt.3 Since basic
elements of sepsis treatment, including
deﬁnitive antibiotic therapy, adequate ﬂuids
and vasopressors, have not changed for
decades,4 5 new effective therapies are des-
perately needed.
Strengths and limitations of this study
▪ This is a protocol for a systematic review and
evidence synthesis of randomised trials evaluat-
ing the impact of polymyxin-B immobilised hae-
moperfusion (PMX-HP) on outcomes in sepsis/
septic shock.
▪ We have assembled a strong interprofessional
team to perform this systematic review that
includes clinical content experts, methodology
experts and a research librarian experienced in the
performance of high-quality systematic reviews.
▪ We have developed a rigorous peer-reviewed
high-yield literature search strategy to identify
relevant randomised trial for inclusion.
▪ The search results may yield numerous small
clinical trials with significant clinical and statis-
tical heterogeneity that may present challenges
for interpretation.
▪ This systematic review is an important initial step
in the assessment of PMX-HP technology that
will inform clinical practice guidelines for recom-
mendations on its usage as an adjuvant therapy
of sepsis/septic shock in the clinical practice
guidelines.
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Description of the intervention
Experimental animal models of peritonitis have been
used to understand the pathophysiological mechanisms
involved in sepsis and septic shock. Among these
mechanisms, endotoxin, one of the components on the
outer membrane of gram-negative bacteria, is recognised
as a potent mediator of the host response in sepsis. A
study measuring endotoxin levels in patients with septic
shock found that high levels of endotoxin activity were
associated with worse clinical outcomes.6
Polymyxin (PMX) is a cyclic cationic polypeptide anti-
biotic with high afﬁnity for endotoxin. A novel strategy
whereby PMX is bound and immobilised to polystyrene
ﬁbres in a haemoperfusion device was developed in
Japan.7 8
How the intervention might work
The suggested mechanism of action of PMX haemoper-
fusion (PMX-HP) is to remove circulating endotoxin by
adsorption, which limits and disrupts the maladaptive
host response to infection and the progression of the
biological cascade of sepsis.
Why it is important to do this review
The role of endotoxin in sepsis is well established in the
literature.9 10 Some clinical trials have shown that
PMX-HP can improve the physiological proﬁle of
patients with abdominal sepsis.11 12 In a small pilot
study, cardiac index and oxygen delivery index were
improved in patients treated with PMX-HP.11 In a multi-
centre Italian trial, Cruz et al12 showed that PMX-HP
improved blood pressure and decreased dose require-
ment for vasopressor support. However, it has not been
determined whether they offer any clinically important
beneﬁts and actually translate into improved outcomes
for patients. Individual studies tend to focus on surro-
gate outcomes or be underpowered to detect effects on
clinically important outcomes.13 A number of additional
studies have been completed evaluating the efﬁcacy,
safety and effectiveness of PMX-HP, including a larger
multicentre RCT.14 15 Accordingly, we propose to
perform an up-to-date systematic review and evidence
synthesis evaluating the impact of PMX-HP as an adju-
vant therapy for critically ill patients with sepsis or septic
shock on clinical outcomes and health services usage.
Objectives
To assess efﬁcacy, safety and effectiveness of PMX-HP for
adult patients with sepsis or septic shock.
METHODS AND ANALYSIS
Study design
We will perform a systematic review and meta-analysis,
using the guidelines from the Cochrane Collaboration
and Centre for Reviews and Dissemination, and
described according to the PRISMA-P guideline (see
online supplementary appendix 1).
Study registration
The systematic review protocol has been registered with
the PROSPERO International Prospective Register
of Systematic Reviews (http://www.crd.york.ac.uk/
prospero), and will be reported using Preferred
Reporting Items for Systematic review and Meta-Analysis
protocols.16 Registration number CRD42016038356.
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials that investigate
the effect of PMX-HP for patients with sepsis or septic
shock will be included. We will also include cluster-
randomised trials if the intracluster correlation coefﬁ-
cient is reported. We will exclude crossover studies
because of the nature of sepsis requiring intensive treat-
ment within a short period. We will also exclude
quasi-randomised studies. We will include studies
reported as full text, those published as an abstract only
and unpublished data.
Types of participants
Adults aged 18 years or older with sepsis or septic shock
will be included. Studies that included a minority
(<10%) of patients under 18 years, or studies with
median or mean of age of patients over 20 years will be
included.
The diagnosis of sepsis or septic shock will be based
on the diagnosis with documented or clinically sus-
pected systemic infection. Septic shock will be classically
deﬁned as a hypotension resistant to ﬂuid administra-
tion requiring norepinephrine or other vasopressor.17
Patients who developed sepsis or septic shock after
surgery will also be included.
Participants of any gender and ethnicity and who are
treated in any setting will be included.
Types of interventions
The interventions will be the use of the PMX-HP ﬁbre
column for the treatment of sepsis or septic shock.
Comparison will be performed between the patients
who receive standard treatment plus PMX-HP (PMX-HP
group) and the patients with standard treatment only or
sham haemoperfusion (Control group).
Types of outcome measures
Primary outcomes:
1. 28-day all-cause mortality
2. Serious adverse events, deﬁned as hypotension or
massive bleeding
3. Changes in organ dysfunction scores (Changes in
Sequential Organ Failure Assessment (SOFA) score
over 72 hours after the treatment)
Secondary outcomes:
1. 90-day all-cause mortality
2. Changes in mean arterial blood pressure over 72 hours
after the treatment
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3. Changes in endotoxin levels over 72 hours after the
treatment
4. Duration of vasopressor therapy or 28-day
vasopressor-free days
5. Duration of RRT
6. ICU length of stay
7. Cost related to health services
Search methods for identification of studies
PROSPERO was searched for any registered systematic
reviews on this topic (26 May 2016).
Electronic searches
The search strategy was developed in consultation with a
research librarian at the Alberta Research Centre for
Health Evidence (ARCHE) at the University of Alberta
and underwent peer review by another research librar-
ian.18 A draft of the search strategy is available in online
supplementary appendix 2. We will obtain all relevant
studies irrespective of language or publication status
(published, unpublished, in press and in progress) from
the following databases: MEDLINE (Ovid), EMBASE
(Ovid), Cochrane Library, Health Technology
Assessment Database (HTA), Cumulative Index to
Nursing and Allied Health Literature (CINAHL),
PubMed and ‘Igaku Chuo Zasshi (ICHUSHI)’.
ICHUSHI is a bibliographic database that was estab-
lished in 1903 and is being updated by the Japan
Medical Abstracts Society, a non-proﬁt and non-
governmental body (http://www.jamas.or.jp/about/
english.htm). ICHUSHI contains bibliographic citations
and abstracts from more than 2500 biomedical journals
and other serial publications published in Japan. We will
modify the MEDLINE search strategy for searching all
the other databases. For ongoing trials, we will search
the National Institute of Health Clinical Trials Register
(https://clinicaltrials.gov/), the WHO International
Clinical Trials Registry Platform (http://www.who.int/
ictrp/en/) and the University Hospital Medical
Information Network Clinical Trials Registry (http://
www.umin.ac.jp/ctr/).
Searching other resources
We will manually search citations from all included
studies. We will contact authors of the identiﬁed trials if
necessary to inquire about unpublished studies. We will
also contact experts in the ﬁeld and selected industries
that develop or license PMX-HP to identify additional
unpublished and ongoing trials. If necessary, we will also
search conference proceedings and manufacturer
websites.
Data collection and analysis
Selection of studies
Two review authors (TF and RG) will independently
screen titles and abstracts of all studies we identiﬁed by
the search and code them as ‘retrieve’ (eligible or
potentially eligible/unclear) or ‘do not retrieve’. We will
retrieve their full texts and identify studies for inclusion
and record reasons for exclusion of the ineligible
studies. We will resolve any disagreement through discus-
sion or, if required, we will consult a third person (YK or
SMB). Agreement between the two review authors in
determining study eligibility will be reported as percent-
age agreement and weighted κ. We will identify and
exclude duplicates of the same study so that each study
rather than each report is the unit of interest in the
review.
Data extraction and management
We will use a standardised data extraction form for study
characteristics and outcome data that has been piloted
on at least one study in the review. Two review authors
(TF and RG) will extract data from the included studies
independently. Agreement between the two reviewers
concerning the primary outcomes will be reported as
percentage agreement and intraclass correlation coefﬁ-
cients. Agreement between the two reviewers in the risk
of bias items will be reported as percentage agreement
and weighted κ. Any disagreement will be resolved
through discussion, or discussed with a third person (YK
or SMB) if necessary. We will abstract the following infor-
mation: study characteristics, patient characteristics,
sample size, interventions, comparators, potential biases
in the conduct of the trial, outcomes including adverse
events, methods of statistical analysis, clinical trial regis-
tration and funding support.
Literature search results will be uploaded to Rayyan
Software (https://rayyan.qcri.org/), an internet-based
software program that facilitates collaboration among
reviewers to select with titles and abstracts. Prior to the
formal screening process, a calibration exercise will be
undertaken to pilot and reﬁne the screening sheet.
Analyses will be performed using Review Manager
Software (V.5.3, Cochrane Collaboration, http://tech.
cochrane.org/RevMan) and GRADEpro GDT, http://
gradepro.org/.
Assessment of risk of bias in included studies
At least two reviewers will independently assess the risk
of bias of the included studies using the tool described
in the Cochrane Handbook for Systematic Reviews of
Interventions.19 The domains listed in box 1 will be
assessed.
The risk of bias, in each domain and overall, will be
assessed as shown in table 1. When inadequate details of
randomisation and other characteristics of trials are pro-
vided, the risk of bias will be classiﬁed as unclear unless
further information can be obtained by contacting the
authors. If the assessors disagree, the ﬁnal rating will be
made by discussion or with the involvement of another
member of the review group, if necessary. A study will be
classiﬁed as being at low risk of attrition bias when data
for all randomised patients are available. In the case of
dropouts, a study may still be assessed as being at low
risk of attrition bias when:
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▸ Missing outcome data are few and balanced in
numbers across intervention groups, with similar
reasons for missing data across groups;
▸ Reasons for missing outcome data are unlikely to be
related to true outcome;
▸ Missing data have been imputed using appropriate
methods.
Whenever possible, study protocols will be retrieved in
order to assess the risk of reporting bias. A study will be
considered to be at low risk of reporting bias when the
study protocol is available and all of the study’s prespeci-
ﬁed outcomes that are of interest in the review have
been reported in the prespeciﬁed way. When the study
protocol is not available, the study will be classiﬁed as
being at unclear risk of reporting bias unless reported
information is sufﬁcient to make a judgement.
Measures of treatment effect
Dichotomous outcomes
As the measure of treatment effect for dichotomous out-
comes, we will use the RR and its 95% CI because of its
favourable mathematical properties. Graphical displays
for meta-analysis performed on ratio scales will use a log
scale.
Continuous outcomes
The unit of measurement to be used in the included
studies will be identical. Data will therefore be pooled by
calculating the mean difference (MD) with 95% CI.
Unit of analysis issues
Crossover trials
Clinical trials with a crossover design will be excluded in
this review.
Cluster-randomised trials
Cluster-randomised trials will be included in this review
as long as proper adjustment for the intracluster correl-
ation is conducted.19 We will reduce the size of each
trial to its effective sample size. A common design effect
will be assumed across intervention groups. For dicho-
tomous data, both the number of participants and the
number experiencing the event should be divided by
the same design effect. For continuous data, only the
sample size needs to be reduced; means and SDs should
remain unchanged.
Multiple intervention groups
Where multiple trial arms are reported in a single trial,
arms will be combined as long as they can be regarded
as subtypes of the same haemoperfusion therapy. When
arms cannot be regarded as if in each of them a differ-
ent subtype of the same intervention is administered, we
will include only the relevant arms. In such a case, a
single pairwise comparison will be used to avoid a unit
of analysis error. For dichotomous outcomes, data from
a different dosage of the same relevant active interven-
tion arms will be summed into a single arm for compari-
son. For continuous outcomes, means and SDs will be
combined.19
Dealing with missing data




The proportion of treatment failure will be calculated
using an intention-to-treat following the principle ‘once
randomised always analysed’. To this end, all randomised
patients for whom outcome data are not available will be
assumed as treatment failures. Any assumptions and
imputations to handle missing data will be clearly stated,
and the effect of imputation will be explored by sensitiv-
ity analyses.
Continuous outcomes
An available cases analysis will be performed for patients
with a ﬁnal assessment presented by the original
authors.
Missing statistics
When only p values or SE values are reported, we will
calculate SDs according to Altman.20 If none of these
values are available, and in the absence of online
supplementary data after requests to the authors, the
SDs will be calculated from CIs, t values or p values;19 or
they will be imputed from other studies in the
meta-analysis according to a validated method.21 We will
examine the validity of these imputations in a sensitivity
analysis. Where actual p values obtained from t-tests are
reported, the corresponding t value will be obtained
from a table of the t distribution.
Box 1 Domains for assessment of the risk of bias
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (assessment bias).
5. Incomplete outcome data reporting (attrition bias).
6. Selective outcome reporting (reporting bias).
7. Sponsorship bias.
8. Other biases (Cointervention imbalance).
Table 1 Assessment of the risk of bias
The risk
of bias Explanation
Low risk Plausible bias unlikely to seriously alter the
results
Unclear risk Insufficient information to determine whether
the risk of bias is low or high
High risk Plausible bias that seriously weakens
confidence in the results
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Assessment of heterogeneity
We will assess overall heterogeneity by visual inspection
of the forest plots. We will also assess statistical hetero-
geneity using the I2 statistic (on a scale of 0% to 100%)
and χ2 test. I2 values above 50% will be considered to
represent substantial statistical heterogeneity and be
explored further. However, the importance of the
observed I2 depends on the magnitude and direction of
treatment effects and the strength of evidence for het-
erogeneity.19 Since the χ2 test has low power when
studies have a small sample size or are few in number,
we will use a p value of 0.10 to determine statistical sig-
niﬁcance. To provide an indication of the spread of true
investigation effects, we will also report between-study
variance in a random-effects meta-analysis using τ2. For
absolute measures of effect, an approximate 95% range
of underlying effects can be obtained by creating an
interval from 1.96×τ below the random-effects pooled
estimate, to 1.96×τ above it.
Assessment of reporting biases
We will undertake comprehensive searches of multiple
sources (including trial registries), increasing efforts to
identify the unpublished materials and including
non-English language publications as far as possible, to
minimise the impact of reporting biases. We will also try
to identify outcome reporting bias in trials by recording
all trial outcomes, planned and reported, and noting
where outcomes were missing. When we ﬁnd evidence
of missing outcomes, we will attempt to obtain any avail-
able data directly from the authors. Where this is not
possible, and the missing data are thought to introduce
serious bias, the impact of including such studies in the
overall assessment of results will be explored by a sensi-
tivity analysis. Funnel plots will be constructed, and
visual inspection will be performed to investigate the
asymmetry. When 10 or more trials are pooled for
primary outcomes, tests for funnel plot asymmetry will
be used to investigate the potential inﬂuence of report-
ing biases and small-study effects.
Data synthesis
Meta-analyses will be performed should a sufﬁcient
number of studies (three or more) are found that share
study design and measurement of comparators; other-
wise, we will describe the results from each studies.
Given the likelihood of differing underlining disorders
in the population of interest, such as abdominal sepsis
and others, a random-effects model will be used in all
analyses.22
Subgroup analysis and investigation of heterogeneity
We expect considerable heterogeneity for the primary
outcomes, and we will use subgroup and meta-regression
analyses as exploratory tools to explain them. Exploring
sources of heterogeneity may result in false-positive con-
clusions through multiple analyses. Since these analyses
lack power, they are more likely to result in false-negative
results. Giving thought to these limitations, we will
perform the following a priori subgroup analyses for the
participant group and intervention if sufﬁcient detail is
present in the eligible studies.
Participants
▸ Abdominal sepsis versus sepsis with other aetiologies
▸ Culture positive sepsis versus others
▸ Conﬁrmed gram-negative sepsis versus others
▸ Patients with high-level endotoxin activity deﬁned as
endotoxin activity assay ≥0.6 vs low-level endotoxin
activity
▸ Surgical patients versus medical patients
▸ Sepsis versus septic shock
▸ Patients with acute kidney injury (AKI) versus others
We will use the formal statistical test for heterogeneity
across subgroup based on a random-effects model to test
for subgroup interaction.
Intervention
▸ Single session versus two sessions versus more than
two sessions
▸ Less than 2 hours versus 2 hours versus longer than
2 hours
Sensitivity analysis
To determine the sensitivity of the ﬁndings to the way in
which we have conducted the analysis, we will perform
sensitivity analyses in the following areas.
1. Risk of bias: We will include only trials with a low risk
of bias in allocation concealment.
2. Imputed missing data: We will exclude trials for
which missing data are imputed.
3. Statistical method of data synthesis: a random-effects
model versus ﬁxed-effect model.
Summary of findings tables
We will assess the quality of the body of evidence using
the Grading of Recommendations Assessment,
Development and Evaluation (GRADE).23 We will
present the results of the review in the ‘Summary of
Findings’ tables including the following outcomes: 28-day
all-cause mortality, serious adverse events, changes in
organ dysfunction scores, 90-day all-cause
mortality, changes in mean arterial blood pressure over
72 hours after the treatment, duration of vasopressor
therapy or vasopressor-free days, and cost related to
health services.
Ethics and dissemination
The study will evaluate the clinical effect of PMX-HP for
patients with sepsis/septic shock from available pub-
lished and unpublished clinical trial data. Since no
primary data are collected, formal health research ethics
approval is not required. The study will be disseminated
by peer-reviewed publication and conference presenta-
tion. If our protocol needs to be amended, the date,
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details of the change and the rationale will be documen-
ted in the revised protocol and updated on PROSPERO.
DISCUSSION
The role of endotoxin in sepsis is well established in the
literature.9 10 PMX-HP was developed to remove and
clear circulating endotoxin,2 3 which leads to decreases
in inﬂammatory cytokines and mediators. PMX-HP has
also been reported to adsorb activated neutrophils24 and
monocytes25 in patients with sepsis. A variety of small
open-label clinical trials have been published with gener-
ally promising results.13 Nevertheless, data from previous
studies should be considered as inconclusive, as those
trials inherit a high risk of bias, that is, underpowered or
unblinded. The purpose of our planned systematic
review is to determine efﬁcacy, safety and effectiveness of
PMX-HP for adult patients with sepsis or septic shock.
The key strength of this protocol is its comprehensive
search for relevant studies, including ongoing trials14
and unpublished data. No language restriction will be
placed and a thorough search in the databases in the
country where PMX-HP was developed will enable a
data comprehensive review to update our knowledge.
There are several expected limitations for this review.
First, we deﬁned sepsis as documented or clinically sus-
pected systemic infection and septic shock as
sepsis-induced hypotension persisting despite ﬂuid resusci-
tation, in line with the well-known deﬁnition.17 A new def-
inition for sepsis was proposed recently,26 and future
research on sepsis might use this new deﬁnition. To
address the issue of variation in participants in interpreting
and applying the results, we propose to perform a sub-
group analyses for the participants according to endotoxin
activity levels. Second, the results of this review will depend
on the quality of the studies we identify, which might be
low as in the previous review.13 We will, therefore, perform
sensitivity analyses to see whether the ﬁndings will change
depending on the risk of bias of each study. Finally, small
studies with high heterogeneity could make it difﬁcult to
interpret the obtained results.
However, we expect the present review to provide the
most comprehensive and up-to-date critical summary of
available evidence regarding the use of PMX-HP for
sepsis or septic shock in the ICU and will help guide
treatment recommendations of sepsis or septic shock in
the clinical practice guidelines.5
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